Novartis | NOVN - Zinsaufwendungen Für Schuld

Aktienkurs
123.17
Täglich Wechseln
0.27 0.22%
Monatlich
-2.56%
Jährlich
26.59%
Q2 Prognose
116.14




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Alcon AG USD 54M 3M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Autolus Therapeutics Ltd USD 10.52M 17.35M 2025-09
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Fresenius EUR 81M 5M 2025-09
Fresenius Medical Care EUR 85M 8.1M 2025-12
Galapagos EUR 1.72M 940K 2025-09
Genmab DKK 10M 27M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
GRIFOLS EUR 141.43M 61.28M 2025-06
Hikma Pharmaceutical USD 67M 47M 2025-12
J&J USD 18M 290M 2025-09
Lonza CHF 84M 14M 2025-06
Merck EUR 121M 5M 2025-12
Merck USD 412M 85M 2025-12
Novartis USD 304M 23M 2025-12
Novartis USD 281M 8M 2025-09
Novo Nordisk DKK 1.53B 3.43B 2025-09
Orion EUR 600K 600K 2025-09
Pfizer USD 711M 59M 2025-12
Philips EUR 109M 31M 2025-12
Recordati EUR 22.13M 1.43M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR -25M 252M 2025-12
UCB EUR 49M 29M 2025-12